Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference
Halozyme Therapeutics, Inc. (HALO) will be presenting at the Barclays 2015 Global Healthcare Conference in Miami, FL on March 10, 2015 at 1:05 p.m. ET/10:05 a.m. PT. David A. Ramsay, Chief Financial Officer, will provide a corporate overview.
The presentation will be webcast through the “Investors” section of Halozyme’s corporate website at www.halozyme.com, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme’s website approximately 15 minutes prior to the presentation to register and download any necessary audio software.
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme’s lead proprietary program, our investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer and non-small cell lung cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE™, which enables biologics and small molecule compounds that are currently administered intravenously to be delivered subcutaneously. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/halozyme-therapeutics-to-present-at-the-barclays-2015-global-healthcare-conference-300044935.html